Background. Aerosolized administrations of amphotericin B deoxycholate (AmBd) and amphotericin B lipid complex (ABLC) in lung transplant recipients were compared for safety and tolerability. The incidence of invasive fungal infections in patients receiving aerosolized amphotericin B formulations as sole prophylaxis was determined.
Invasive fungal infections (IFIs) in patients undergoing lung transplantation are relatively common and have been associated with significant attributable mortality (1, 2) . Therefore, several antifungal prophylactic strategies have been used in an attempt to reduce the impact of IFIs on patient survival. However, the use of systemic antifungal therapies may be limited by lack of in vitro activity against Aspergillus sp (fluconazole), drug interactions (itraconazole, voriconazole), significant treatment-limiting toxicities, and requirements for intravenous administration (amphotericin B, caspofungin) (1) (2) (3) .
The use of inhaled aerosols of amphotericin B as prophylaxis in humans has been reported in various populations for amphotericin B deoxycholate (AmBd) (4 -7) and amphotericin B lipid complex (ABLC) (8) . However, intolerance leading to treatment discontinuation has been reported to be as high as 48% in one report with AmBd (6) . In contrast, we previously demonstrated a low rate of adverse events with aerosolized ABLC in a noncomparative study in lung transplant recipients (8) . Therefore, it is important to compare the safety of various formulations of amphotericin B when used prophylactically in patients at increased risk of IFIs to determine the best preparation for use.
The primary objective of our study was to compare the safety and tolerability of inhaled aerosols of AmBd and ABLC in lung transplant recipients. A secondary objective of this study was to observe the incidence of IFIs in these patients receiving aerosolized inhaled formulations of amphotericin B as sole antifungal prophylaxis in the early postlung-transplant period.
MATERIALS AND METHODS
This randomized, double-blind, single-center study was reviewed and approved by the Duke University Medical Center Institutional Review Board. Consenting male and nonpregnant, nonlactating females 18 to 65 years of age undergoing lung or heart-lung transplantation were included in the trial. Those with a history of hypersensitivity to amphotericin B or liposomal preparations (excluding infusion-related reactions, renal, hematologic, or electrolyte disturbances after amphotericin B infusions), those unwilling or unable to comply with aerosolized drug administration, documented prior active IFIs (excluding colonization), mycetomas, or concomitant systemic antifungal therapy were excluded. This project was supported by an unrestricted educational grant from Elan Pharmaceuticals. Dr. Benjamin received support from NICHD R03HD42940 -01.
Informed consent was obtained from patients or their parents or guardians and human experimentation guidelines of the US Department of Health and Human Services and Duke University Medical Center Institutional Review Board were followed in the conduct of clinical research.
Study treatment was initiated as soon as possible after lung transplantation. Patients were allowed to receive routine treatments with ipratropium or albuterol before study drug administration. Concomitant use of the nonabsorbable antifungal agent nystatin was also permitted. Treatment assignment was performed by sequential assignment from a computer-generated randomization list with a 1:1 treatment assignment. The treatment identity was known only to the research pharmacist. Amphotericin B (Fungizone, Bristol-Myers Squibb, Stamford, CT) in 50 mg vials was reconstituted with 10 mL of sterile water for injection, USP. ABLC (Abelcet, Enzon Pharmaceuticals, Bridgewater, NJ) in a 100 mg/20 mL suspension was drawn up using a filter needle supplied with the preparation. The completed preparations were placed in amber-colored syringes. Patients requiring mechanical ventilation received a 20 mL administration containing either ABLC 100 mg or AmBd 50 mg. Extubated patients received a 10 mL volume containing either ABLC 50 mg or AmBd 25 mg by way of a mouthpiece. Study treatments were administered by way of a nebulizer (Hudson RCI Up-Draft, Model No 1724, Hudson Respiratory Care, Temecula, CA) and aerosolized with compressed air at a flow rate of 7 to 8 L/min and inhaled over at least 10 to 15 minutes (until finished) once every day for 4 days, then once per week for 7 weeks (total 11 doses). Study drug was discontinued prematurely for drug intolerance, withdrawal of permission, or need for systemic antifungal therapy. Longer prophylaxis periods were permitted outside the study using open-labeled therapies at the discretion of the investigator.
Immediately before each drug administration, we obtained a limited medical history from chart review and (whenever possible) a patient interview. This review included identification of active fungal infections and concomitant antifungal therapy. We also completed a detailed pulmonary examination and measurement of pulmonary function. For patients not requiring mechanical ventilation, we obtained a measurement of forced expiratory volume in 1 second (FEV 1 ), defined as the obvious plateau in volume-time curve resulting in no changes in FEV 1 for at least 2 seconds and exhalation time of at least 6 seconds. The maximal value of at least two concordant spirometric measurements was used. We also obtained peak flow and forced vital capacity (FVC) measurements. For patients requiring mechanical ventilation, dynamic compliance and peak and plateau airway pressures were measured. Measurements of pulmonary mechanics were repeated within 5 minutes of study drug administration. In extubated patients, the presence or absence of the following signs and subjective symptoms within 5 minutes before and after each treatment were recorded: cough, dyspnea, nausea, vomiting, and taste perversion.
Standard postoperative care throughout the study consisted of triple immunosuppressive therapy (i.e., tacrolimus or cyclosporine, azathioprine and prednisone) as well as tailored antibacterial prophylaxis and cytomegalovirus (CMV) prophylaxis with ganciclovir and CMV immune globulin as indicated. All patients also received prophylaxis against Pneumocystis pneumonia. Patients underwent routine bronchoscopy with bronchoalveolar lavage (BAL) within 24 hours of transplantation and when clinically indicated. Additional surveillance bronchoscopies were repeated (during the study period) at 1 month for routine care. Samples of BAL fluid were routinely sent for viral, fungal, and bacterial cultures. Additional clinical specimens, as well as radiologic and serologic investigations, were performed in patients suspected of IFI. Patients were followed for a total of 2 months after initiation of study drug administration.
All randomized subjects were included in the analysis. Descriptive statistics were used for patient demographics and the incidence of study drug-related adverse events. We compared the following primary outcome measures (specified before study initiation) between the two populations: (1) incidence of study drug intolerance requiring treatment discontinuation and (2) number of subjects experiencing one or more adverse events. We prespecified adverse events as expiratory wheeze, cough, shortness of breath, taste perversion, nausea, vomiting, or bronchospasm. We prespecified bronchospasm as a postreatment decrease of 20% or more in dynamic compliance (for ventilated participants) or in either FEV 1 or FVC (for extubated participants). Relationships of adverse events to study drugs were based on available clinical information and the consensus opinion of at least two study investigators (JP and SP). For the secondary outcome, we described the following information within 2 months posttransplantation: (1) description and incidence of IFIs and (2) incidence of primary prophylaxis failure requiring initiation of systemic antifungal therapy. For purposes of this study, the following definitions were applied: (1) primary failure-need for treatment of an IFI (9) . For the analysis of the number of participants who experienced at least one adverse event, the unit of observation was the participant, and reported p values are two-tailed and based on chi-square. For the analysis of total adverse events, the unit of observation is the treatment administered, and we used a generalized estimating equation (GEE) (10, 11) to compare the incidence of adverse effects between therapies. GEE is a regression technique that accounts for multiple observations for each individual. In the GEE regression, we used an unstructured within-group correlation matrix. The outcome was adverse event for a given treatment (coded 0/1), and the independent variable was treatment (coded 0-ABLC/1-AmBd). For the results presented in this study, we used binomial distribution and logit link (a procedure analogous to logistic regression). We repeated the analysis using Poisson and negative binomial distributions (with log link) and obtained similar results. All reported p values and confidence intervals (CI) are two-tailed.
RESULTS
Between June 1999 and August 2002, 157 consecutive pulmonary allograft recipients were screened to yield a total of 100 eligible and consenting subjects. Of the 100 enrolled subjects, 8 were withdrawn before completing study drug therapy for the following reasons: administrative (not related to failure or study drug intolerance, 5 participants) and adverse events unrelated to study drug administration (3 participants). Patient demographics for each group are summarized in Table 1 . The overall mean (ϮSD) age of the participants was 51.1Ϯ13.3 years. Subjects in the trial were predominantly male (56.0%) and white (91.0%). The most frequent underlying illnesses were chronic obstructive pulmonary disease (39.0%), idiopathic pulmonary fibrosis (22.0%), and cystic fibrosis (16.0%). The majority of participants (83.0%) underwent bilateral lung transplantation, with two of these patients undergoing bilateral retransplantation. Excluding the one patient not receiving study drug administration (withdrawn because of the need for systemic antifungal therapy), the meanϮSD number of treatments in AmBd and ABLC treatment groups were 6.8Ϯ2.7 and 6.7Ϯ2.3, respectively. The median durations of therapy (range) were 39.0 (1-56) and 35.0 (0 -58) days in the two treatment groups, respectively.
A summary of the safety and tolerability of study drug therapy is found in Table 2 . Among the treatments with complete study drug tolerability documentation, shortness of breath (worsening from pretreatment) was the most common study-related side effect, occurring in 19.9% and 2.1% of AmBd and ABLC-treated participants, respectively. This was followed in incidence by cough (10.6% vs. 2.1%) and taste perversion (10.6% vs. 7.7%) in the two groups, respectively. A total of 14 (28.6%) participants experienced one or more treatment-related adverse effect from AmBd compared with 7 (13.7%) in the ABLC group. One or more episodes of bronchospasm were observed in 25.0% and 20.4%, respectively. Treatment-related adverse events requiring study drug discontinuation occurred in 12.2% and 5.9% of the groups, respectively. To detect an absolute difference of 7% in the incidence of study drug intolerance requiring treatment discontinuation (powerϭ0.80, alphaϭ0.05), 275 participants in each arm (nϭ550) would have been required. Given the limitation of the sample in this trial, we had only 20% power (alphaϭ0.05) to detect an absolute difference of 7% (13% in the AmBd arm and 6% in the ABLC arm) in the discontinuation because of study drug intolerance.
Of the 49 participants who received AmBd, 21 had an adverse event (42%; 95% CI 0.29, 0.58), and 14 of 50 participants who were randomized and received ABLC (28%; 0.16, 0.42) experienced an adverse event. Using GEE regression to evaluate all doses administered, participants who received AmBd were more likely to experience an adverse event (odds ratio [OR] 2.16; 95% CI 1.10, 4.24;
Pϭ0.02)
A description of IFIs is found in Table 3 . Primary prophylaxis failure was reported in seven (14.3%) participants treated with AmBd, while six (11.8%) participants receiving ABLC failed therapy. Only two participants experienced primary prophylaxis failure because of Aspergillus infections, both of whom were found to have anastomosis infections. In all, only four participants required any systemic antifungal therapy during the study for this mould.
DISCUSSION
The reported incidence of IFIs in lung transplant recipients has ranged from 16% to 44% (1, 2, 12, 13) . The infection rate is probably influenced by several factors, such as the period of observation, type and degree of immunosuppression, environmental exposure, and technical aspects of the surgery (1, 2, 12 ). For example, exposures to Aspergillus spores from contaminated air conditioning systems and in hospital areas undergoing construction and renovations have been described and thus emphasize variability of infections between medical centers. Furthermore, donor lungs can also be the source of fungal infections (1) . Dormant fungi in the asymptomatic donor lung can be reactivated to produce infection during the period of immunosuppression (1).
Given the incidence of disease and mortality associated with IFIs in this population, a prophylactic strategy has become justified in most medical centers (3, 12) . AmBd, although a mainstay of systemic treatment for documented IFIs, has significant limitations as a prophylactic strategy because of its requirements for parenteral administration, infusion-related reactions, electrolyte wasting, and nephrotoxicity (14) . Amphotericin B-induced nephrotoxicity is of particular concern in patients receiving concomitant immunosuppressive nephrotoxic agents such as cyclosporine (15) . Azoles (itraconazole, fluconazole, and voriconazole) have acceptable safety profiles and are available for both oral and parenteral administration. In contrast with fluconazole, itraconazole demonstrates favorable activity both in vitro and in clinical studies against Aspergillus sp. However, its absorption after oral administration may be unreliable (particularly with the tablet formulation), necessitating the need for serum concentration monitoring (16, 17) . Although voriconazole also possesses favorable in vitro and clinical activity against Aspergillus sp, both itraconazole and voriconazole have limitations because of potential drug interactions with cyclosporine and the potential for toxicity of their vehicle when the intravenous formulations are administered to patients with moderate-severe renal insufficiency (16 -18) .
To avoid the systemic toxicities of parenteral amphotericin B, alternative routes of administration have been investigated for both the prevention and treatment of IFIs. Local therapy into the lung by way of inhalation of aerosols containing amphotericin B could be extremely useful as a prophylactic strategy in specific patients at increased risk for IFIs (19) . In animal models of pulmonary aspergillosis, aerosolized AmBd significantly delayed mortality compared with controls as a treatment strategy (20, 21) . However, the human experience with alternate routes of amphotericin B administration as prophylaxis (which includes intranasal administration) has met mixed success. Perhaps the most widely published human experience with such prophylaxis is in the administration of aerosolized AmBd in patients with prolonged periods of granulocytopenia (4 -7) . These trials, which used a variety of doses, frequencies, and nebulizers for administration, have yielded conflicting results as to the role of aerosolized AmBd efficacy in preventing IFIs. Although the incidence of IFIs is frequently reported to be either similar or lower than with the use of aerosolized AmBd, use of concomitant oral antifungal prophylaxis, frequent need for empiric systemic antifungal therapy, and lack of randomized controlled trials make such conclusions problematic. Despite 61% of lung transplant centers reporting the use of aerosolized amphotericin B as prophylaxis for lung transplants in a recent survey (22) , published experience with aerosolized AmBd in lung transplant patients for prophylaxis is limited (3, 23, 24) . For instance, the use of aerosolized AmBd was reported at a dose of 20 mg three times daily in a group of 126 lung, heart-lung, and heart transplant recipients (24) . A significant reduction in the rate of fungal infections at 3 and 12 months was noted when compared with a historic control cohort of 101 patients receiving transplants before the introduction of aerosolized amphotericin B prophylaxis. Calvo et al. (3) reported no IFIs in 52 lung transplant recipients receiving aerosolized AmBd at 0.2 mg/kg administered every 8 hours (in combination with fluconazole). Finally, Monteforte and colleagues report their experience with the use of AmBd at 6 mg every 8 hours for 120 days, then daily thereafter in 44 lung transplant recipients (23) . In their study, receipt of nebulized AmBd resulted in a significant reduction in the risk of Aspergillus infections (OR 0.13; 95% CI 0.02-0.69).
Although most published reports of aerosolized amphotericin B fail to include objective measurements of patient tolerance, Dubois and colleagues (25) reported their experience with 18 patients receiving 132 aerosolized AmBd treatments. Nine instances of clinically significant bronchospasm (defined by a reduction in peak flow of Ͼ20%) were reported, and 4 of 18 patients discontinued therapy because of gastrointestinal toxicity. Other investigators have also reported on the tolerability of aerosol AmBd treatments (4, 6, 26) . In one such report, coughing (54%), bad taste (51%), and nausea (37%) caused early cessation of aerosol amphotericin B prophylaxis in 23% (15/65) of courses (4) . Other reports of prophylactic aerosolized AmBd in patients with hematologic malignancies also suggest these formulations were poorly tolerated (6) . In the study by Erjavec and colleagues (6), 43% of patients experienced at least one side effect, and 12% discontinued its use. However, all reports cite that the incidence of severe side effects were minimal.
The potential advantages of lipid-based formulations of amphotericin B over AmBd for aerosolization would be the relative ease of drug delivery (because these agents are in solution and do not tend to foam during nebulization), potential for enhanced tissue penetration, and a reduction in treatment-related side effects (27) . In general, published data regarding the pharmacokinetics of aerosolized formulations of amphotericin B in animal models suggest increased amphotericin B tissue concentrations when lipid-based preparations are used when compared with AmBd (28, 29) . Animal model data have reported favorable results when used as prophylaxis for both liposomal amphotericin B (21) and ABLC (29) compared with either placebo or AmBd. However, human data regarding the administration of lipid-based formulations of amphotericin B for prophylaxis is scarce. We previously reported our experience with administration of aerosolized ABLC in 51 lung transplant recipients receiving no other form of systemic antifungal therapy (8) . Although the study was performed to evaluate the safety and tolerability of the therapy, the authors reported that four patients developed anastomotic fungal infections, whereas eight patients developed extrapulmonary fungal infections. However, no infections with Aspergillus were reported. The treatment was subjectively well-tolerated in 98% of patients, with bronchospasm (defined as a worsening in pulmonary mechanics of Ն20%) reported in less than 5% of all treatments (8) . Only one subject discontinued treatment because of intolerance, and in this study, 3 of 51 (5.9%) discontinued treatment with ABLC.
In this single-center study, we were able to observe the prevalence of IFIs in a series of lung transplant recipients receiving aerosolized polyenes. Because a placebo arm was not used, we cannot measure the true efficacy of aerosol antifungals in preventing fungal infections. With our strategies, pulmonary infections in the first 2 months posttransplant are infrequent. There are occasional anastomotic and pleural infections, with prevalence rates under 10%, which is consistent with our previous experience (8) . Because amphotericin B was not detectable in serum after aerosol administration of ABLC in our prior study (8), we did not assume that extrapulmonary infections would be prevented. One may hypothesize that the addition of systemic antifungal prophylaxis to aerosol therapy may have prevented these infections. Such questions should be evaluated by future clinical trials. However, in this cohort, there were only 5% of patients who developed these infections within the study period. A trial of 5,700 patients would be required to show a difference in the observed rates of invasive disease. At this rate, it is difficult to justify the need for systemic antifungal prophylaxis in the uninfected, noncolonized patient without defining additional risk factors. However, it is important to emphasize that there was a series of patients who were colonized or whose donor's lung was colonized (approximately 10%) in whom directed systemic prophylaxis was used (Table 3) . Also, in our experience, patients receiving extracorporeal membrane oxygenation have a high rate of disseminated candidiasis and should therefore receive systemic antifungal prophylaxis. Therefore, it is important to further define risk factors for IFI in lung transplant recipients because there may be subsets of patients who need systemic prophylactic or preemptive strategies. However, our experiences lead us to hypothesize that for a routine lung transplant recipient without additional risk factors receiving aerosolized polyenes, very few lung or anastomotic infections are observed.
There are limitations of our study that are worth noting. First, our limited follow-up period (2 months) does not permit the description of fungal infections in patients beyond the study prophylaxis period. Second, diagnostic interventions in this study were based on "standard of care" investigation and thus lack serial and consistent mycologic surveillance. Third, we were faced with diagnostic challenges, such as determining the level of fungal invasion and differentiating colonization versus infection in certain "high-risk" patients with other potential etiologies of illness. Fourth, it is also important to emphasize that this study is a prophylaxis study. Therefore, this study does not define the role of aerosolized polyenes in the treatment of established infections. Finally, the true efficacy of aerosol polyene prophylaxis in lung transplant recipients requires a placebo-controlled study. The distribution and pharmacokinetics of either preparation was not studied. The optimal dose, du-ration, and delivery system for aerosolized polyene prophylaxis have yet to be established. CONCLUSION We observed that that both AmBd and ABLC administered by aerosol after lung transplantation appear to be associated with an acceptable rate of IFIs in the immediate posttransplant period. Although changes in pulmonary mechanics do not appear to differ between the two agents, ABLC is associated with a reduced rate of drug intolerance compared with AmBd, which may be important to the care of these complex and seriously ill patients.
